SUZHOU FUSHILAI PHARMACEUTICAL CO., LTD.

Suzhou Fushilai Pharmaceutical Co., Ltd.

301258

CNE1000058W2

Pharmaceuticals

End-of-day quote Shenzhen S.E. Other stock markets 18:00:00 2024-07-04 EDT			5-day change	1st Jan Change
25.01 ^CNY	+3.48%		+0.60%	-22.52%

07-01	Tranche Update on Suzhou Fushilai Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on February 6, 2024.	CI
06-05	Suzhou Fushilai Pharmaceutical Co., Ltd. Announces Implementation of Final Profit Distribution Plan (A Shares) for 2023, Payable on 12 June 2024	CI

Tranche Update on Suzhou Fushilai Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on February 6, 2024.

July 01, 2024 at 05:18 am

From April 1, 2024 to June 30, 2024, the company has repurchased 125,000 shares, representing 0.14% for CNY 2.92 million. With this, the company has completed the repurchase of 135,000 shares, representing 0.15% for CNY 3.17 million under the buyback announced on February 6, 2024.

Latest news about Suzhou Fushilai Pharmaceutical Co., Ltd.

Tranche Update on Suzhou Fushilai Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on February 6, 2024.	07-01	CI
Suzhou Fushilai Pharmaceutical Co., Ltd. Announces Implementation of Final Profit Distribution Plan (A Shares) for 2023, Payable on 12 June 2024	06-05	CI
Suzhou Fushilai Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	04-22	CI
Tranche Update on Suzhou Fushilai Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on February 6, 2024.	04-01	CI
Certain A Shares of Suzhou Fushilai Pharmaceutical Co., Ltd. are subject to a Lock-Up Agreement Ending on 29-MAR-2024.	03-28	CI
Suzhou Fushilai Pharmaceutical Co., Ltd. announces an Equity Buyback for CNY 40 million worth of its shares.	02-06	CI
Suzhou Fushilai Pharmaceutical Co., Ltd. authorizes a Buyback Plan.	02-04	CI
Fushilai Pharmaceutical Co., Ltd. announced that it expects to receive CNY 200 million in funding from Suzhou Fushilai Pharmaceutical Co., Ltd.	12-17	CI
Suzhou Fushilai Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	23-10-19	CI
Suzhou Fushilai Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-21	CI
Suzhou Fushilai Pharmaceutical Co., Ltd. Announces Cash Dividend on A Shares for 2022, Payable on 08 June 2023	23-06-01	CI
Suzhou Fushilai Pharmaceutical Co., Ltd. Approves the Cash Dividend for the Year 2022	23-05-10	CI
Suzhou Fushilai Pharmaceutical Co., Ltd. Proposes Final Cash Dividend for the Year 2022	23-04-18	CI
Suzhou Fushilai Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-04-17	CI
Suzhou Fushilai Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	23-04-17	CI
Certain A Shares of Suzhou Fushilai Pharmaceutical Co., Ltd. are subject to a Lock-Up Agreement Ending on 29-MAR-2023.	23-03-28	CI
Fushilai Pharmaceutical to Apply for 375 Million Yuan Credit Lines This Year	23-03-16	MT
Suzhou Fushilai Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022	22-10-25	CI
Suzhou Fushilai Pharmaceutical Co., Ltd. Approves Management Appointments	22-09-13	CI
Suzhou Fushilai Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022	22-08-22	CI
Suzhou Fushilai Pharmaceutical Co., Ltd. Final Announces Cash Dividend on A Shares for 2021, Payable on June 8, 2022	22-06-01	CI
Suzhou Fushilai Pharmaceutical Co., Ltd. Approves Cash Dividend for 2021	22-05-19	CI
Suzhou Fushilai Pharmaceutical Co., Ltd. Proposes Profit Distribution for 2021	22-04-27	CI
Suzhou Fushilai Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-04-26	CI
Suzhou Fushilai Pharmaceutical Co., Ltd. has completed an IPO in the amount of CNY 1.107036 billion.	22-03-23	CI

Chart Suzhou Fushilai Pharmaceutical Co., Ltd.

Duration

Period

Chart Suzhou Fushilai Pharmaceutical Co., Ltd.

More charts

Company Profile

Suzhou Fushilai Pharmaceutical Co Ltd is a China-based company mainly engaged in the production and sales of pharmaceuticals. The Company is mainly engaged in the research and development, production and sales of pharmaceutical intermediates, active pharmaceutical ingredients (APIs) and raw materials for health care products. The Company's main products include three series of lipoic acid series, phosphatidylcholine series and carnosine series. The Company mainly conducts its business in domestic and overseas markets such as Europe, America, Japan and South Korea, India and South America.

Sector

Pharmaceuticals

Calendar

2024-08-22 - Q2 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
SUZHOU FUSHILAI PHARMACEUTICAL CO., LTD.	-22.52%	315M
ELI LILLY AND COMPANY	+56.89%	823B
NOVO NORDISK A/S	+39.52%	627B
JOHNSON & JOHNSON	-6.55%	353B
MERCK & CO., INC.	+15.99%	320B
ABBVIE INC.	+7.92%	295B
ASTRAZENECA PLC	+13.74%	239B
NOVARTIS AG	+13.83%	220B
ROCHE HOLDING AG	-0.49%	219B
AMGEN INC.	+7.94%	167B